Teva makes $40 billion offer for Mylan
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
List view / Grid view
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
23 September 2013 | By Teva
The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.
3 April 2013 | By GlobalData
India is becoming a key market for generic medicines...
2 August 2012 | By Gilead Sciences, Inc.
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements...
30 April 2012 | By Teva Pharmaceutical Industries Ltd
TEVA, has settled patent infringement litigation with Mylan Inc.'s ANDA for Teva’s wakefulness product NUVIGIL® (armodafinil) tablets...
27 April 2012 | By Merck
"The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid..."
20 May 2011 | By Cephalon Inc
The United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon and Eurand for a TRO enjoining Mylan Pharmaceuticals and Mylan from manufacturing, using and selling its cyclobenzaprine hydrochloride extended-release capsules...